LBIO Lion Biotechnologies Inc

Robbins Arroyo LLP: Lion Biotechnologies, Inc. (LBIO) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Lion Biotechnologies, Inc. (NasdaqGM: LBIO) in the U.S. District Court for the Northern District of California. The complaint is brought on behalf of all purchasers of Lion securities between November 14, 2013 and April 10, 2017, for alleged violations of the Securities Exchange Act of 1934 by Lion's officers and directors. Lion, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/lion-biotechnologies-inc

Lion Accused of Engaging in Illegal Stock Promotion Scheme

According to the complaint, Lion attested in its public filings to the accuracy of financial reporting, the disclosure of any material changes to the company's internal controls over financial reporting, and the disclosure of all fraud. On May 14, 2014, Lion stated in its 1Q 2014 Form 10-Q that it received a subpoena from the U.S. Securities and Exchange Commission ("SEC") seeking information concerning "documents and communications related to individuals who post or have posted articles regarding the Company on equity research or other financial websites." On April 10, 2017, the SEC found that Lion, through its former Chief Executive Officer Manish Singh ("Singh") engaged in a scheme to mislead investors by commissioning over ten internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company, when, in fact, they were paid promotions. Further, Singh engaged a stock promotion firm to pay writers to publish articles about Lion on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes.

Lion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

EN
11/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 22,810 shares of Iovance’s common stock to two new, non-executi...

 PRESS RELEASE

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: 2025 Wells Fargo Healthcare ConferenceFireside Chat: September 5, 2025 at 8:00 a.m. ETBoston, MA H.C. Wainwright 27th Annual Global Investment ConferencePresentation: September 9, 2025 ...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance’s common stock to 20 new, non-executive e...

 PRESS RELEASE

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Ad...

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced Health Canada has issued a Notice of Compliance with Conditions (...

 PRESS RELEASE

Iovance Biotherapeutics Reports Financial Results and Corporate Update...

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch